Section Arrow
Quote
PCRX.NASDAQ
- Pacira BioSciences
Quotes are at least 15-min delayed:2026/06/03 05:52 EDT
Pre Market
Last
 22.35
+0.1 (+0.45%)
Bid
22
Ask
22.45
High 22.7 
Low 21.01 
Volume 281 
Regular Hours (Closed)
Last
 22.25
-0.71 (-3.09%)
Day High 
23.1625 
Prev. Close
22.96 
1-M High
25.6 
Volume 
345.43K 
Bid
22
Ask
22.45
Day Low
22.215 
Open
22.96 
1-M Low
21.92 
Market Cap 
903.43M 
Currency 美元 
P/E 171.15 
%Yield -- 
10-SMA 23.28 
20-SMA 23.38 
50-SMA 23.65 
52-W High 27.64 
52-W Low 18.8 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
0.13/4.00
Enterprise Value
1.31B
Balance Sheet
Book Value Per Share
16.62
Cash Flow
Cash Flow Yield
0.14
Income Statement
Total Revenue
726.41M
Operating Revenue Per Share
16.92
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
HIMSHims & Hers Health27.51-0.25-0.90%-- 
Pre Market 26.98 -0.53 -1.93%
ESPREsperion Therapeutics3.14+0.01+0.32%-- 
Pre Market 3.13 -0.01 -0.32%
SBFMSunshine Biopharma Inc2.6+0.21+8.79%-- 
Pre Market 2.48 -0.12 -4.62%
TEVATeva Pharmaceutical Industries Limited33.08-1.56-4.50%24.69PE
Pre Market 33.08 0 0.00%
VTRSViatris15.69-0.12-0.76%-- 
Pre Market 15.5 -0.19 -1.21%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.